Fresenius Medical Care will purchase a 19% stake in Humacyte, which closed a $75m series C round in March 2018.

Tony Hickson, currently the managing director of Imperial Innovations, will become chief business officer of Cancer Research UK in August.

Polycera was spun out from Water Planet, itself a spinout of UCLA, and was established to commercialise polymer membranes for water filtration.

Sensome develops micro-sensor systems for medical devices which exploit impedance together with machine learning algorithms to reliably identify biological tissues.

Cambridge Enterprise has returned to back Silicon Microgravity, which builds on collaborative research between the university and BP.

The UCL spinout has set the pricing range at $15 to $17 and stands to raise nearly $144m in proceeds if underwriters take up their 30-day option.

Investors in the series B round included TUS Holdings, FAW and Contemporary Amperex Technology.

The Cornell spinout has emerged from stealth with funding from GV and New Enterprise Associates.

Duke spinout Precision BioSciences, whose investors include Amgen and Baxter, has raised an initial $88m in series B funding out of a $110m target.

Forty Seven, a GV-backed immuno-oncology spinout from Stanford University, has filed for a $115m initial public offering on Nasdaq just eight months after closing a $75m series B.